Vir Biotechnology, Inc. (VIR) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $17.00K; Additional Paid in CapitalUSD $2.23B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.60M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $2.14B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.48M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $1.97B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.06M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $1.95B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.91M.
Vir Biotechnology, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Split USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $17.00K | $2.23B | $-4.60M | $-1.24B | $982.49M | $982.49M | 6 month · $10.29M | 3 month · $12.39M 6 month · $24.48M | (m) |
| 2026-03-31 | $0.00 | $16.00K | $2.14B | $-3.48M | $-1.32B | $812.76M | $812.76M | 3 month · $10.15K | 3 month · $12.09M | (m) |
| 2025-12-31 | $0.00 | $14.00K | $1.97B | $-2.06M | $-1.20B | $765.28M | $765.28M | (m) | 12 month · $49.07M | (m) |
| 2025-09-30 | $0.00 | $14.00K | $1.95B | $-1.91M | $-1.15B | $796.10M | $796.10M | (m) | 3 month · $11.36M 9 month · $37.87M | (m) |
| 2025-06-30 | $0.00 | $14.00K | $1.94B | $-2.22M | $-991.71M | $947.47M | $947.47M | (m) | 3 month · $12.45M 6 month · $26.51M | (m) |
| 2025-03-31 | $0.00 | $14.00K | $1.93B | $-1.98M | $-880.75M | $1.04B | $1.04B | (m) | 3 month · $14.06M | (m) |
| 2024-12-31 | $0.00 | $14.00K | $1.91B | $-1.72M | $-759.78M | $1.15B | $1.15B | (m) | 12 month · $78.46M | (m) |
| 2024-09-30 | $0.00 | $14.00K | $1.89B | $1.13M | $-655.20M | $1.24B | $1.24B | (m) | 3 month · $16.70M 9 month · $62.62M | (m) |
| 2024-06-30 | $0.00 | $14.00K | $1.88B | $-2.88M | $-441.48M | $1.43B | $1.43B | (m) | 3 month · $22.16M 6 month · $45.92M | (m) |
| 2024-03-31 | $0.00 | $14.00K | $1.85B | $-2.40M | $-303.10M | $1.55B | $1.55B | (m) | 3 month · $23.76M | (m) |
| 2023-12-31 | $0.00 | $13.00K | $1.83B | $-815.00K | $-237.82M | $1.59B | $1.59B | (m) | 12 month · $111.32M | (m) |
| 2023-09-30 | $0.00 | $13.00K | $1.80B | $-1.90M | $-121.85M | (m) | $1.68B | (m) | 3 month · $26.94M 9 month · $83.04M | (m) |
| 2023-06-30 | $0.00 | $13.00K | $1.77B | $-2.90M | $41.56M | (m) | $1.81B | (m) | 3 month · $30.62M 6 month · $56.10M | (m) |
| 2023-03-31 | $0.00 | $13.00K | $1.74B | $-3.22M | $236.34M | $1.97B | $1.97B | (m) | 3 month · $25.48M | (m) |
| 2022-12-31 | $0.00 | $13.00K | $1.71B | $-9.12M | $377.24M | $2.08B | $2.08B | (m) | 12 month · $102.08M | (m) |
| 2022-09-30 | $0.00 | $13.00K | $1.68B | $-11.88M | $478.84M | $2.15B | $2.15B | (m) | 3 month · $24.81M 9 month · $77.22M | (m) |
| 2022-06-30 | $0.00 | $13.00K | $1.66B | $-7.55M | $303.53M | $1.95B | $1.95B | (m) | 3 month · $27.10M 6 month · $52.40M | (m) |
| 2022-03-31 | $0.00 | $13.00K | $1.63B | $-4.80M | $380.02M | $2.00B | $2.00B | (m) | 3 month · $25.30M | (m) |
| 2021-12-31 | $0.00 | $13.00K | $1.57B | $-1.10M | $-138.60M | $1.43B | $1.43B | (m) | 12 month · $83.78M | (m) |
| 2021-09-30 | (m) | $13.00K | $1.54B | $-1.31M | $-663.85M | $876.27M | (m) | (m) | 3 month · $22.94M 9 month · $59.41M | (m) |
| 2021-06-30 | (m) | $13.00K | $1.51B | $-1.33M | $774.28M | $737.33M | (m) | (m) | 3 month · $21.00M 6 month · $36.47M | (m) |
| 2021-03-31 | (m) | $13.00K | $1.49B | $-1.30M | $-836.10M | $650.95M | (m) | (m) | 3 month · $15.47M | (m) |
| 2020-12-31 | $0.00 | $13.00K | $1.39B | $-1.28M | $-667.18M | $716.85M | $716.85M | (m) | 12 month · $27.60M | (m) |
| 2020-09-30 | (m) | $13.00K | $1.37B | $-485.00K | $-561.53M | $812.36M | (m) | (m) | 3 month · $8.58M 9 month · $17.30M | (m) |
| 2020-06-30 | (m) | $12.00K | $1.04B | $-295.00K | $-476.93M | $563.78M | (m) | (m) | 3 month · $5.75M 6 month · $8.72M | (m) |
| 2020-03-31 | (m) | $11.00K | $825.83M | $248.00K | $-445.76M | $380.33M | (m) | (m) | 3 month · $2.97M | (m) |
| 2019-12-31 | (m) | $11.00K | $793.05M | $-601.00K | $-368.52M | $423.94M | (m) | (m) | 12 month · $8.72M | 12 month · $3.00K |
| 2019-09-30 | (m) | $1.00K | $23.87M | $81.00K | $-304.75M | $-280.80M | (m) | (m) | 3 month · $2.19M 9 month · $6.04M | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-236.97M | (m) | (m) | 3 month · $1.40M 6 month · $3.85M | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-205.22M | (m) | (m) | 3 month · $2.45M | (m) |
| 2018-12-31 | (m) | $1.00K | $14.67M | $-14.00K | $-193.84M | $-179.18M | (m) | (m) | 12 month · $5.05M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $-154.02M | (m) | (m) | 3 month · $1.45M 9 month · $4.10M | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $-122.30M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-68.92M | (m) | (m) | 12 month · $4.78M | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $-7.97M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |